ArticleBiomaterials2019
Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.
Article in Biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 56 citations in OpenAlex.
- An alveolar macrophage-targeted ciprofloxacin polymeric prodrug improves survival in a murine model ofAntimicrobial agents and chemotherapy · 2026Article
- Prodrug-based drug delivery systems: strategic approaches and emerging challenges in targeted therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Metabolic reprogramming of macrophages in chronic obstructive pulmonary disease.Frontiers in immunology · 2025Review
- Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy.Nano today · 2024Article
- Article
- Ag-Activated Metal-Organic Framework with Peroxidase-like Activity Synergistic AgNanomaterials (Basel, Switzerland) · 2022Article
- Selective treatment of intracellular bacterial infections using host cell-targeted bioorthogonal nanozymes.Materials horizons · 2022Article
- Surface Functionalization of Polymer Particles for Cell Targeting by Modifying Emulsifier Chemistry.ACS applied polymer materials · 2022Article
- Beyond "Big Eaters": The Versatile Role of Alveolar Macrophages in Health and Disease.International journal of molecular sciences · 2021Review
- Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021Review
- Macrophage metabolic reprogramming during chronic lung disease.Mucosal immunology · 2021Review
- A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Diversity of Macrophages in Lung Homeostasis and Diseases.Frontiers in immunology · 2021Review
- Mannose Conjugated Polymer TargetingACS infectious diseases · 2020Article
- Decoding glycans: deciphering the sugary secrets to be coherent on the implication.RSC advances · 2020Review
- Aerosol jet printing of biological inks by ultrasonic delivery.Biofabrication · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
Alveolar macrophages resident in the lung are prominent phagocytic effector cells of the pulmonary innate immune response, and paradoxically, are attractive harbors for pathogens. Consequently, facultative intracellular bacteria, such as Francisella tularensis, can cause severe systemic disease and sepsis, with high morbidity and mortality associated with pulmonary infection. Current clinical treatment, which involves exhaustive oral or intravenous antibiotic therapy, has limitations such as systemic toxicity and off-target effects. Pulmonary administration represents a promising alternative to systemic dosing for delivering antibiotics directly to the lung. Here, we present synthesized mannosylated ciprofloxacin polymeric prodrugs for efficient pulmonary delivery, targeting, and subsequent internalization by alveolar macrophages. We demonstrate significant improvement in efficacy against intracellular infections in an otherwise uniformly lethal airborne Francisella murine model (F. novicida). When administered to the lungs of mice in a prophylactic regimen, the mannosylated ciprofloxacin polymeric prodrugs led to 50% survival. In a treatment regimen that was concurrent with infection, the survival of mice increased to 87.5%. Free ciprofloxacin antibiotic was ineffective in both cases. This significant difference in antibacterial efficacy demonstrates the impact of this delivery platform based on improved physiochemical, pharmacokinetic, and pharmacodynamic properties of ciprofloxacin administered via our glycan polymeric prodrug. This modular platform provides a route for overcoming the limitations of free drug and increasing efficacy in treatment of intracellular infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.